Peginterferon lambda-1a
As of the edition of 20 October 2026, Peginterferon lambda-1a is a drug: stopped in 2021; acts on IFNLR1 and IL10RB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Unknown
- Registered trials
- 21, 4 stopped early
- Disease areas
- Infections; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 6 | 0 | 2 |
| Phase 3 | 9 | 5 | 0 | 2 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2007 to now |
| EIT Pharma | Lead sponsor of trials | 2016 to now |
| Eiger BioPharmaceuticals | Lead sponsor of trials | 2021 to now |